ALRN On Other Exchanges

aileron therapeutics inc (ALRN) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aileron therapeutics inc (ALRN) Related Businessweek News

No Related Businessweek News Found

aileron therapeutics inc (ALRN) Details

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company’s lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Watertown, Massachusetts.

23 Employees
Last Reported Date: 03/29/19
Founded in 2001

aileron therapeutics inc (ALRN) Top Compensated Officers

President, CEO & Director
Total Annual Compensation: $674.1K
Senior VP & CFO
Total Annual Compensation: $463.3K
Senior VP & Chief Medical Officer
Total Annual Compensation: $536.6K
Compensation as of Fiscal Year 2018.
aileron therapeutics inc
Aileron Therapeutics, Inc. Provides Update on Information Regarding the Design and Anticipated Timing of Data from Its Ongoing and Planned Clinical Trials of ALRN-6924

On June 5, 2019, Aileron Therapeutics, Inc. announced updated information regarding the design and anticipated timing of data from its ongoing and planned clinical trials of ALRN-6924. The Company is conducting a Phase 2a clinical trial of the combination of ALRN-6924 and palbociclib (Ibrance), marketed by Pfizer, Inc., for the treatment of MDM2-amplified advanced solid tumors. The Company plans to enroll up to 25 patients in this trial. The objectives of this trial include evaluation of the safety, tolerability and activity of the combination, including determination of the overall response rate and other measures of activity including progression-free survival and overall survival. The Company plans to use the data from the trial to identify an indication to investigate in further trials of the combination. The Company plans to disclose interim data from 15 patients enrolled in this trial at the European Society for Medical Oncology Congress 2019, which is scheduled from September 27 through October 1, 2019, and to have final data from all 25 patients in this trial in the second quarter of 2020. Myelopreservation Trial in Combination with Topotecan: In September 2019, the Company plans to begin enrolling patients with advanced small cell lung cancer who are treated with topotecan in a Phase 1b/2 trial of ALRN-6924 to assess ALRN-6924 as a myelopreservative agent protecting against chemotherapy-induced bone marrow toxicity. The Company plans to enroll up to 40 patients in the Phase 1b portion of the trial and, subject to funding, up to 60 patients in the Phase 2 portion of the trial. In the trial, patients will receive administration of ALRN-6924 on days 0-4 and administration of topotecan on days 1-5 of every 21-day treatment cycle. The objectives of the trial include evaluation of the safety and efficacy of ALRN-6924 as a myelopreservative agent, including determining whether patients experience a reduction of grade 3 or greater neutropenia, anemia and thrombocytopenia and reduction of febrile neutropenia. The Company plans to disclose data from the Phase 1b portion of the trial in the second quarter of 2020.

Aileron Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-05-2019 08:00 AM

Aileron Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-05-2019 08:00 AM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: Manuel C. Aivado, President, CEO & Director.

Aileron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

Aileron Therapeutics, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced operating loss was USD 7.313 million compared to USD 7.763 million a year ago. Net loss was USD 7.213 million compared to USD 7.588 million a year ago. Basic loss per share was USD 0.49 compared to USD 0.52 a year ago.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ALRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALRN.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AILERON THERAPEUTICS INC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at